Verastem Oncology to Present at Upcoming Investor Conferences

BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate and present at the following investor conferences in May:

• H.C. Wainwright 3^rd Annual BioConnect Investor Conference: Fireside chat on Tuesday, May 20 at 12:00 pm ET
• 2025 RBC Capital Markets Global Healthcare Conference: Fireside chat on Tuesday, May 20 at 3:35 pm ET
• Alliance Global Partners/A.G.P.’s Annual Healthcare Company Showcase: Virtual fireside chat on Wednesday, May 21 at 10:20 am ET

A live webcast of the fireside chats can be accessed under events on Verastem Oncology’s website at www.verastem.com. A replay of the webcasts will be archived on the website for approximately 90 days following the presentation.

About Verastem Oncology

Verastem Oncology (Nasdaq: VSTM) is a biopharmaceutical company committed to developing and commercializing new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers. Our pipeline is focused on novel small-molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition, FAK inhibition, and KRAS G12D inhibition. For more information, please visit www.verastem.com and follow us on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250501095515/en/

For Investor and Media Inquiries:

Julissa Viana

Vice President, Corporate Communications,

Investor Relations & Patient Advocacy

investors@verastem.com or

media@verastem.com

Source: Verastem Oncology